Preventing Pathogenic Dimerization in a Misfolded Antibody Light Chain through the Design of an Inhibitory Peptide

Area of Science:

• Biochemistry
• Computational Biology
• Drug Discovery

Background:

• Immunoglobulin light chain (AL) amyloidosis is a systemic disease caused by insoluble aggregates of patient-specific antibody light chains.
• The unique hypervariable regions of these light chains necessitate personalized therapeutic approaches.

Purpose of the Study:

• To design a peptide inhibitor targeting a specific pathogenic homodimer found in AL amyloidosis.
• To demonstrate a computational strategy for developing patient-specific peptide antagonists against aggregation-prone proteins.

Main Methods:

• Analysis of the dynamics and interface of a previously identified patient-derived light chain homodimer.
• Computational mutagenesis protocol to iteratively refine a peptide sequence for optimal binding complementarity (shape, electrostatics, hydropathy).

Main Results:

• Identification of a peptide with potential inhibitory activity against the pathogenic dimer.
• The optimized peptide demonstrated binding affinity comparable to the full pathogenic interface.
• The designed peptide acts as an effective antagonist of the pathogenic dimer.

Conclusions:

• The developed computational strategy provides a general framework for designing patient-specific inhibitory peptides.
• The designed peptide shows potential as a therapeutic agent for AL amyloidosis by blocking pathogenic dimer formation.